Enliven Therapeutics (ELVN) Expected to Announce Earnings on Tuesday

Key Points

• Enliven Therapeutics is set to release its Q2 2025 earnings on August 12th, with analysts forecasting earnings of ($0.54) per share for the quarter.
• The company's stock recently traded at $18.96, with a market cap of $930.12 million, and insider transactions showed significant selling activity by executives.
• Brokerages have varying price targets for Enliven Therapeutics, with reports indicating an average target of $41.20 and several analysts rating the stock as a "buy".

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Tuesday, August 12th. Analysts expect Enliven Therapeutics to post earnings of ($0.54) per share for the quarter.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.06). On average, analysts expect Enliven Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Enliven Therapeutics Price Performance

Shares of NASDAQ ELVN traded down $0.21 during midday trading on Friday, reaching $17.69. 574,228 shares of the stock traded hands, compared to its average volume of 386,894. The stock has a market capitalization of $868.05 million, a PE ratio of -9.21 and a beta of 0.93. Enliven Therapeutics has a one year low of $13.30 and a one year high of $30.03. The company's 50 day moving average is $20.84 and its 200 day moving average is $19.98.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ELVN. Robert W. Baird increased their price target on Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a report on Monday, June 16th. HC Wainwright increased their target price on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research note on Wednesday, July 2nd. The Goldman Sachs Group started coverage on Enliven Therapeutics in a research note on Monday, June 16th. They issued a "buy" rating and a $37.00 target price on the stock. Finally, Jones Trading reduced their target price on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Enliven Therapeutics presently has an average rating of "Buy" and an average price target of $41.20.

Insider Buying and Selling at Enliven Therapeutics

In other news, CEO Samuel Kintz sold 12,500 shares of the business's stock in a transaction dated Thursday, July 17th. The stock was sold at an average price of $22.52, for a total transaction of $281,500.00. Following the sale, the chief executive officer owned 940,392 shares in the company, valued at approximately $21,177,627.84. The trade was a 1.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Anish Patel sold 6,667 shares of the business's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $20.34, for a total value of $135,606.78. Following the sale, the chief operating officer owned 303,309 shares in the company, valued at $6,169,305.06. The trade was a 2.15% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 99,084 shares of company stock worth $2,046,719 over the last quarter. Insiders own 25.90% of the company's stock.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ELVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Enliven Therapeutics by 8.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company's stock worth $428,000 after buying an additional 1,693 shares during the period. Jane Street Group LLC acquired a new position in shares of Enliven Therapeutics during the 1st quarter worth approximately $578,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of Enliven Therapeutics by 61.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company's stock worth $4,167,000 after buying an additional 80,506 shares during the period. Institutional investors and hedge funds own 95.08% of the company's stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.